Month: May 2025

OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms

Written by Customer Service on May 13, 2025. Posted in Public Companies.

MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value...

Cycurion Secures $33 Million Contract Renewal to Enhance Cybersecurity for State-Level Public Higher Education Institutions

Written by Customer Service on May 13, 2025. Posted in Public Companies.

MCLEAN, Va., May 13, 2025 (GLOBE NEWSWIRE) — Cycurion (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity solutions and AI, announces that it has been awarded a significant contract renewal by a major state-level public higher education group. Under this renewed agreement, Cycurion will deliver comprehensive cybersecurity services to member universities and colleges within the group, ensuring they are equipped to defend their education-focused operations and digital assets against the ever-evolving landscape of cyber threats. The renewal, valued at $33 million over the five-year term, extends Cycurion’s partnership through November 2030. Comprehensive Cybersecurity Services As part of this renewed contract, Cycurion will provide an extensive suite of cybersecurity and governance, risk, and compliance...

Interim Management Statement covering Q3 2024/25

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Interim Management Statement covering Q3 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2025– 31 March 2025) of the financial year 2024/25. Q3 highlightsIn Q3 2024/25, the revenue amounted to DKK 7.5 million (Q3 2023/24: DKK 9.5 million).EBITDA in Q3 amounted to DKK -0.4 million (Q3 2023/24: DKK 0.8 million).Order intake in Q3 amounted to DKK 9.3 million. During Q3 and to date, the Company signed new contracts for the ESA EnVision mission with prime contractor Thales Alenia Space and a new commercial contract with The Exploration Company for the Independent Software Validation and Verification (ISVV) of the software for their modular & reusable NyX space vehicle. Total order intake in the period January until end of April amounts...

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Preparations on track for Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer, with submission expected in Q4 2026 Recently announced both prolonged median overall survival (mOS) and a long tail of survival in an open label phase 2a clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) patients, non-responsive to immune checkpoint inhibitor (ICI) treatment, particularly those patients with non-squamous histology Recently announced notable improvement in mOS after experimental treatment with CAN-2409 compared to the control...

Lido Merger Sub, Inc. Announces Commencement of Tender Offer and Consent Solicitation for 8.875% Senior Notes due 2029 of Landsea Homes Corporation

Written by Customer Service on May 13, 2025. Posted in Mergers And Acquisitions.

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) — Lido Merger Sub, Inc. (the “Company”) announced today that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of Landsea Homes Corporation’s (“Landsea Homes”) outstanding 8.875% Senior Notes due 2029 (the “Notes”). In connection with the Tender Offer, the Company is also soliciting the consents of holders of the Notes to certain proposed amendments to the indenture governing the Notes (the “Consent Solicitation”). The Company is commencing the Tender Offer and the Consent Solicitation in connection with, and each is expressly conditioned upon, the consummation of the acquisition of Landsea Homes pursuant to the Agreement and Plan of Merger, dated May 12, 2025 (as amended, supplemented, waived or otherwise modified from time to time), by and among Landsea Homes,...

TRESU Investment Holding A/S – Annual General Meeting 2025

Written by Customer Service on May 13, 2025. Posted in Public Companies.

TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 06.2025 13.05.2025 TRESU Investment Holding A/S – Annual General Meeting 2025 On the annual general meeting 2025 of Tresu Investment Holding A/S the following decisions were made:The audited annual report for 2024 was adopted. In accordance with the proposal by the Board of Directors, the loss as recorded in the annual report was appropriated. Jean-Marc Denis Lechene, Søren Dan Johansen, Ola Harald Erici and Stephan Hubert Plenz were re-elected as members of the Board of Directors. PriceWaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as auditor of the company. The Board of Directors and the Executive Board were discharged from liability.The general meeting had specifically waived the requirement for notice and presentation of documents under the Danish...

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Written by Customer Service on May 13, 2025. Posted in Public Companies.

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos’ development partner GSK assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally...

Landstar System Reports First Quarter Revenue of $1.153B and Earnings per Share of $0.85 and Announces 11% Increase to Quarterly Dividend

Written by Customer Service on May 13, 2025. Posted in Dividend Reports And Estimates.

JACKSONVILLE, Fla., May 13, 2025 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ: LSTR) (“Landstar” or the “Company”) today reported basic and diluted earnings per share (“EPS”) of $0.85 in the 2025 first quarter on revenue of $1.153 billion. “The Landstar team of independent business owners and employees continued to perform admirably, despite a highly unpredictable macro-economic backdrop,” said Landstar President and Chief Executive Officer Frank Lonegro. “I was encouraged by the number of loads hauled via truck in the quarter. Importantly, this was the first time in fifteen years that the number of loads hauled via truck during the first quarter exceeded the immediately preceding fourth quarter. Our network of Landstar BCOs, agents and employees are laser-focused on safety, security and delivering great service to our customers...

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, May 13, 2025 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2025 financial results and provided a corporate update. Recent Highlights:ImmuneOnco’s Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC in China is ongoing and ImmuneOnco anticipates initial clinical data from first-line NSCLC patients...

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Written by Customer Service on May 13, 2025. Posted in Earnings Releases And Operating Results.

Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clinical radiopharmaceutical therapeutics. “Notwithstanding the need to gather additional clinical data for iopofosine I 131, as previously announced,...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals